{
  "pmid": "41596178",
  "title": "Microbial Metabolism of Levodopa as an Adjunct Therapeutic Target in Parkinson's Disease.",
  "abstract": "",
  "journal": "Antioxidants (Basel, Switzerland)",
  "year": "2026",
  "authors": [
    {
      "lastName": "Feix",
      "foreName": "Jimmy B",
      "initials": "JB",
      "affiliation": ""
    },
    {
      "lastName": "Cheng",
      "foreName": "Gang",
      "initials": "G",
      "affiliation": ""
    },
    {
      "lastName": "Hardy",
      "foreName": "Micael",
      "initials": "M",
      "affiliation": ""
    },
    {
      "lastName": "Kalyanaraman",
      "foreName": "Balaraman",
      "initials": "B",
      "affiliation": ""
    }
  ],
  "keywords": [
    "Parkinsonâ€™s disease",
    "TPP+-based drugs",
    "levodopa",
    "microbiome",
    "mitochondria-targeted drugs"
  ],
  "doi": "10.3390/antiox15010120",
  "pmcId": "PMC12838373",
  "meshTerms": [],
  "rawXml": "<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2025//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd\">\n<PubmedArticleSet>\n<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\"><PMID Version=\"1\">41596178</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Print\">2076-3921</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month><Day>17</Day></PubDate></JournalIssue><Title>Antioxidants (Basel, Switzerland)</Title><ISOAbbreviation>Antioxidants (Basel)</ISOAbbreviation></Journal><ArticleTitle>Microbial Metabolism of Levodopa as an Adjunct Therapeutic Target in Parkinson's Disease.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">120</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.3390/antiox15010120</ELocationID><Abstract><AbstractText>Parkinson's disease is the second leading neurodegenerative disease of aging. For over five decades, oral levodopa has been used to manage the progressive motor deficits that are the hallmark of the disease. However, individual dose requirements are highly variable, and patients typically require increased levodopa dosage as the disease progresses, which can cause undesirable side effects. It has become increasingly apparent that the gut microbiome can have a major impact on the metabolism and efficacy of therapeutic drugs. In this Perspective, we examine recent studies highlighting the impact of metabolism by <i>Enterococcus faecalis</i>, a common commensal gut bacterium, on levodopa bioavailability. <i>E. faecalis</i> expresses a highly conserved tyrosine decarboxylase that promiscuously converts levodopa to dopamine in the gut, resulting in decreased neuronal uptake of levodopa and reduced dopamine formation in the brain. Mitochondria-targeted antioxidants conjugated to a triphenylphosphonium moiety have shown promise in transiently suppressing the growth of <i>E. faecalis</i> and decreasing microbial levodopa metabolism, providing an approach to modulating the microbiome that is less perturbing than conventional antibiotics. Thus, mitigating metabolism by the gut microbiota is an attractive therapeutic target to preserve and potentiate the efficacy of oral levodopa therapy in Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Feix</LastName><ForeName>Jimmy B</ForeName><Initials>JB</Initials><Identifier Source=\"ORCID\">0000-0002-6389-4262</Identifier><AffiliationInfo><Affiliation>Department of Biophysics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cheng</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biophysics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hardy</LastName><ForeName>Micael</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0003-2976-7785</Identifier><AffiliationInfo><Affiliation>ICR (UMR 7273), CNRS, Aix-Marseille Universit&#xe9;, 13013 Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kalyanaraman</LastName><ForeName>Balaraman</ForeName><Initials>B</Initials><Identifier Source=\"ORCID\">0000-0002-9180-8296</Identifier><AffiliationInfo><Affiliation>Department of Biophysics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=\"Y\"><Grant><GrantID>1R21NS137244-01A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2026</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antioxidants (Basel)</MedlineTA><NlmUniqueID>101668981</NlmUniqueID><ISSNLinking>2076-3921</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN=\"N\">TPP+-based drugs</Keyword><Keyword MajorTopicYN=\"N\">levodopa</Keyword><Keyword MajorTopicYN=\"N\">microbiome</Keyword><Keyword MajorTopicYN=\"N\">mitochondria-targeted drugs</Keyword></KeywordList><CoiStatement>Balaraman Kalyanaraman and Micael Hardy are inventors of US Patent No. 10,836,782/European Patent No. 3307254, &#x201c;Mito-honokiol compounds and methods of synthesis and use thereof.&#x201d; The other authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2025</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2026</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2026</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2026</Year><Month>1</Month><Day>28</Day><Hour>7</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2026</Year><Month>1</Month><Day>28</Day><Hour>7</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2026</Year><Month>1</Month><Day>28</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pmc-release\"><Year>2026</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">41596178</ArticleId><ArticleId IdType=\"doi\">10.3390/antiox15010120</ArticleId><ArticleId IdType=\"pii\">antiox15010120</ArticleId><ArticleId IdType=\"pmc\">PMC12838373</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fearnley J.M., Lees A.J. Ageing and Parkinson&#x2019;s disease: Substantia nigra regional selectivity. Brain. 1991;114:2283&#x2013;2301. doi: 10.1093/brain/114.5.2283.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/brain/114.5.2283</ArticleId><ArticleId IdType=\"pubmed\">1933245</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloem B.R., Okun M.S., Klein C. Parkinson&#x2019;s disease. Lancet. 2021;397:2284&#x2013;2303. doi: 10.1016/S0140-6736(21)00218-X.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(21)00218-X</ArticleId><ArticleId IdType=\"pubmed\">33848468</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W., Hamilton J.L., Kopil C., Beck J.C., Tanner C.M., Albin R.L., Ray Dorsey E., Dahodwala N., Cintina I., Hogan P., et al. Current and projected future economic burden of Parkinson&#x2019;s disease in the U.S. npj Park. Dis. 2020;6:15.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7347582</ArticleId><ArticleId IdType=\"pubmed\">32665974</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorsey E.R., Bloem B.R. The Parkinson Pandemic-A Call to Action. JAMA Neurol. 2018;75:9&#x2013;10. doi: 10.1001/jamaneurol.2017.3299.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamaneurol.2017.3299</ArticleId><ArticleId IdType=\"pubmed\">29131880</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenchov R., Sasso J.M., Zhou Q.A. Evolving Landscape of Parkinson&#x2019;s Disease Research: Challenges and Perspectives. ACS Omega. 2025;10:1864&#x2013;1892. doi: 10.1021/acsomega.4c09114.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1021/acsomega.4c09114</ArticleId><ArticleId IdType=\"pmc\">PMC11755173</ArticleId><ArticleId IdType=\"pubmed\">39866628</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandemakers W., Morais V.A., De Strooper B. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J. Cell Sci. 2007;120:1707&#x2013;1716. doi: 10.1242/jcs.03443.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1242/jcs.03443</ArticleId><ArticleId IdType=\"pubmed\">17502481</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker W.D., Jr., Swerdlow R.H. Mitochondrial dysfunction in idiopathic Parkinson disease. Am. J. Hum. Genet. 1998;62:758&#x2013;762. doi: 10.1086/301812.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1086/301812</ArticleId><ArticleId IdType=\"pmc\">PMC1377050</ArticleId><ArticleId IdType=\"pubmed\">9529370</ArticleId></ArticleIdList></Reference><Reference><Citation>Blesa J., Trigo-Damas I., Quiroga-Varela A., Jackson-Lewis V.R. Oxidative stress and Parkinson&#x2019;s disease. Front. Neuroanat. 2015;9:91. doi: 10.3389/fnana.2015.00091.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fnana.2015.00091</ArticleId><ArticleId IdType=\"pmc\">PMC4495335</ArticleId><ArticleId IdType=\"pubmed\">26217195</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang K.H., Chen C.M. The Role of Oxidative Stress in Parkinson&#x2019;s Disease. Antioxidants. 2020;9:597. doi: 10.3390/antiox9070597.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/antiox9070597</ArticleId><ArticleId IdType=\"pmc\">PMC7402083</ArticleId><ArticleId IdType=\"pubmed\">32650609</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha E.M., De Miranda B., Sanders L.H. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson&#x2019;s disease. Neurobiol. Dis. 2018;109:249&#x2013;257. doi: 10.1016/j.nbd.2017.04.004.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.nbd.2017.04.004</ArticleId><ArticleId IdType=\"pubmed\">28400134</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian M., Li J., Liu T., Hou K., Sun L., Wei J. beta-Synuclein Intermediates alpha-Synuclein Neurotoxicity in Parkinson&#x2019;s Disease. ACS Chem. Neurosci. 2024;15:2445&#x2013;2453. doi: 10.1021/acschemneuro.4c00263.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1021/acschemneuro.4c00263</ArticleId><ArticleId IdType=\"pubmed\">38905183</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H., Kanthasamy A., Ghosh A., Anantharam V., Kalyanaraman B., Kanthasamy A.G. Mitochondria-targeted antioxidants for treatment of Parkinson&#x2019;s disease: Preclinical and clinical outcomes. Biochim. Biophys. Acta. 2014;1842:1282&#x2013;1294. doi: 10.1016/j.bbadis.2013.09.007.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.bbadis.2013.09.007</ArticleId><ArticleId IdType=\"pmc\">PMC3961561</ArticleId><ArticleId IdType=\"pubmed\">24060637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekstrand M.I., Terzioglu M., Galter D., Zhu S., Hofstetter C., Lindqvist E., Thams S., Bergstrand A., Hansson F.S., Trifunovic A., et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl. Acad. Sci. USA. 2007;104:1325&#x2013;1330. doi: 10.1073/pnas.0605208103.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1073/pnas.0605208103</ArticleId><ArticleId IdType=\"pmc\">PMC1783140</ArticleId><ArticleId IdType=\"pubmed\">17227870</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotzias G.C., Van Woert M.H., Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 1967;276:374&#x2013;379. doi: 10.1056/NEJM196702162760703.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJM196702162760703</ArticleId><ArticleId IdType=\"pubmed\">5334614</ArticleId></ArticleIdList></Reference><Reference><Citation>Iversen S.D., Iversen L.L. Dopamine: 50 years in perspective. Trends Neurosci. 2007;30:188&#x2013;193. doi: 10.1016/j.tins.2007.03.002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.tins.2007.03.002</ArticleId><ArticleId IdType=\"pubmed\">17368565</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahn S., Poewe W. Levodopa: 50 years of a revolutionary drug for Parkinson disease. Mov. Disord. 2015;30:1&#x2013;3. doi: 10.1002/mds.26122.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/mds.26122</ArticleId><ArticleId IdType=\"pubmed\">25488146</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitfield A.C., Moore B.T., Daniels R.N. Classics in chemical neuroscience: Levodopa. ACS Chem. Neurosci. 2014;5:1192&#x2013;1197. doi: 10.1021/cn5001759.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1021/cn5001759</ArticleId><ArticleId IdType=\"pubmed\">25270271</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa-induced dyskinesias. Mov. Disord. 2007;22:1379&#x2013;1389. doi: 10.1002/mds.21475.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/mds.21475</ArticleId><ArticleId IdType=\"pubmed\">17427940</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Lloret S., Negre-Pages L., Damier P., Delval A., Derkinderen P., Destee A., Meissner W.G., Tison F., Rascol O., On behalf of the COPARK Study Group L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: The COPARK survey. Eur. J. Neurol. 2017;24:1532&#x2013;1538. doi: 10.1111/ene.13466.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/ene.13466</ArticleId><ArticleId IdType=\"pubmed\">28940893</ArticleId></ArticleIdList></Reference><Reference><Citation>Espay A.J., Morgante F., Merola A., Fasano A., Marsili L., Fox S.H., Bezard E., Picconi B., Calabresi P., Lang A.E. Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. Ann. Neurol. 2018;84:797&#x2013;811. doi: 10.1002/ana.25364.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ana.25364</ArticleId><ArticleId IdType=\"pubmed\">30357892</ArticleId></ArticleIdList></Reference><Reference><Citation>Zappia M., Crescibene L., Arabia G., Nicoletti G., Bagala A., Bastone L., Caracciolo M., Bonavita S., Di Costanzo A., Scornaienchi M., et al. Body weight influences pharmacokinetics of levodopa in Parkinson&#x2019;s disease. Clin. Neuropharmacol. 2002;25:79&#x2013;82. doi: 10.1097/00002826-200203000-00004.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/00002826-200203000-00004</ArticleId><ArticleId IdType=\"pubmed\">11981233</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti V., Izzo V., Russillo M.C., Picillo M., Amboni M., Scaglione C.L.M., Nicoletti A., Cani I., Cicero C.E., De Bellis E., et al. Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naive Patients With Parkinson&#x2019;s Disease. Front. Med. 2022;9:909936. doi: 10.3389/fmed.2022.909936.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fmed.2022.909936</ArticleId><ArticleId IdType=\"pmc\">PMC9193593</ArticleId><ArticleId IdType=\"pubmed\">35712091</ArticleId></ArticleIdList></Reference><Reference><Citation>Contin M., Lopane G., Belotti L.M.B., Galletti M., Cortelli P., Calandra-Buonaura G. Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring. J. Park. Dis. 2022;12:2519&#x2013;2530. doi: 10.3233/JPD-223374.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3233/JPD-223374</ArticleId><ArticleId IdType=\"pmc\">PMC9837688</ArticleId><ArticleId IdType=\"pubmed\">36373294</ArticleId></ArticleIdList></Reference><Reference><Citation>Enright E.F., Gahan C.G., Joyce S.A., Griffin B.T. The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome. Yale J. Biol. Med. 2016;89:375&#x2013;382.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5045146</ArticleId><ArticleId IdType=\"pubmed\">27698621</ArticleId></ArticleIdList></Reference><Reference><Citation>Weersma R.K., Zhernakova A., Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69:1510&#x2013;1519. doi: 10.1136/gutjnl-2019-320204.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/gutjnl-2019-320204</ArticleId><ArticleId IdType=\"pmc\">PMC7398478</ArticleId><ArticleId IdType=\"pubmed\">32409589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta R.S., Mayers J.R., Zhang Y., Bhosle A., Glasser N.R., Nguyen L.H., Ma W., Bae S., Branck T., Song K., et al. Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease. Nat. Med. 2023;29:700&#x2013;709. doi: 10.1038/s41591-023-02217-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41591-023-02217-7</ArticleId><ArticleId IdType=\"pmc\">PMC10928503</ArticleId><ArticleId IdType=\"pubmed\">36823301</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheperjans F., Aho V., Pereira P.A., Koskinen K., Paulin L., Pekkonen E., Haapaniemi E., Kaakkola S., Eerola-Rautio J., Pohja M., et al. Gut microbiota are related to Parkinson&#x2019;s disease and clinical phenotype. Mov. Disord. 2015;30:350&#x2013;358. doi: 10.1002/mds.26069.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/mds.26069</ArticleId><ArticleId IdType=\"pubmed\">25476529</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill-Burns E.M., Debelius J.W., Morton J.T., Wissemann W.T., Lewis M.R., Wallen Z.D., Peddada S.D., Factor S.A., Molho E., Zabetian C.P., et al. Parkinson&#x2019;s disease and Parkinson&#x2019;s disease medications have distinct signatures of the gut microbiome. Mov. Disord. 2017;32:739&#x2013;749. doi: 10.1002/mds.26942.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/mds.26942</ArticleId><ArticleId IdType=\"pmc\">PMC5469442</ArticleId><ArticleId IdType=\"pubmed\">28195358</ArticleId></ArticleIdList></Reference><Reference><Citation>Minato T., Maeda T., Fujisawa Y., Tsuji H., Nomoto K., Ohno K., Hirayama M. Progression of Parkinson&#x2019;s disease is associated with gut dysbiosis: Two-year follow-up study. PLoS ONE. 2017;12:e0187307. doi: 10.1371/journal.pone.0187307.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1371/journal.pone.0187307</ArticleId><ArticleId IdType=\"pmc\">PMC5665539</ArticleId><ArticleId IdType=\"pubmed\">29091972</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov V.A., Saltykova I.V., Zhukova I.A., Alifirova V.M., Zhukova N.G., Dorofeeva Y.B., Tyakht A.V., Kovarsky B.A., Alekseev D.G., Kostryukova E.S., et al. Analysis of Gut Microbiota in Patients with Parkinson&#x2019;s Disease. Bull. Exp. Biol. Med. 2017;162:734&#x2013;737. doi: 10.1007/s10517-017-3700-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10517-017-3700-7</ArticleId><ArticleId IdType=\"pubmed\">28429209</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira P.A.B., Aho V.T.E., Paulin L., Pekkonen E., Auvinen P., Scheperjans F. Oral and nasal microbiota in Parkinson&#x2019;s disease. Park. Relat. Disord. 2017;38:61&#x2013;67. doi: 10.1016/j.parkreldis.2017.02.026.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.parkreldis.2017.02.026</ArticleId><ArticleId IdType=\"pubmed\">28259623</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson&#x2019;s disease. Lancet Neurol. 2003;2:107&#x2013;116. doi: 10.1016/S1474-4422(03)00307-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1474-4422(03)00307-7</ArticleId><ArticleId IdType=\"pubmed\">12849267</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H.Y., Park J.W., Kim J.S. The frequency and severity of gastrointestinal symptoms in patients with early Parkinson&#x2019;s disease. J. Mov. Disord. 2014;7:7&#x2013;12. doi: 10.14802/jmd.14002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.14802/jmd.14002</ArticleId><ArticleId IdType=\"pmc\">PMC4051727</ArticleId><ArticleId IdType=\"pubmed\">24926404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang A.E. A critical appraisal of the premotor symptoms of Parkinson&#x2019;s disease: Potential usefulness in early diagnosis and design of neuroprotective trials. Mov. Disord. 2011;26:775&#x2013;783. doi: 10.1002/mds.23609.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/mds.23609</ArticleId><ArticleId IdType=\"pubmed\">21484865</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundert-Remy U., Hildebrandt R., Stiehl A., Weber E., Zurcher G., Da Prada M. Intestinal absorption of levodopa in man. Eur. J. Clin. Pharmacol. 1983;25:69&#x2013;72. doi: 10.1007/BF00544017.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/BF00544017</ArticleId><ArticleId IdType=\"pubmed\">6617727</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyaue N., Yamamoto H., Liu S., Ito Y., Yamanishi Y., Ando R., Suzuki Y., Mogi M., Nagai M. Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson&#x2019;s disease. npj Park. Dis. 2025;11:49. doi: 10.1038/s41531-025-00903-6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41531-025-00903-6</ArticleId><ArticleId IdType=\"pmc\">PMC11920041</ArticleId><ArticleId IdType=\"pubmed\">40102479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrielli M., Bonazzi P., Scarpellini E., Bendia E., Lauritano E.C., Fasano A., Ceravolo M.G., Capecci M., Rita Bentivoglio A., Provinciali L., et al. Prevalence of small intestinal bacterial overgrowth in Parkinson&#x2019;s disease. Mov. Disord. 2011;26:889&#x2013;892. doi: 10.1002/mds.23566.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/mds.23566</ArticleId><ArticleId IdType=\"pubmed\">21520278</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano A., Bove F., Gabrielli M., Petracca M., Zocco M.A., Ragazzoni E., Barbaro F., Piano C., Fortuna S., Tortora A., et al. The role of small intestinal bacterial overgrowth in Parkinson&#x2019;s disease. Mov. Disord. 2013;28:1241&#x2013;1249. doi: 10.1002/mds.25522.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/mds.25522</ArticleId><ArticleId IdType=\"pubmed\">23712625</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A.H., Mahadeva S., Thalha A.M., Gibson P.R., Kiew C.K., Yeat C.M., Ng S.W., Ang S.P., Chow S.K., Tan C.T., et al. Small intestinal bacterial overgrowth in Parkinson&#x2019;s disease. Park. Relat. Disord. 2014;20:535&#x2013;540. doi: 10.1016/j.parkreldis.2014.02.019.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.parkreldis.2014.02.019</ArticleId><ArticleId IdType=\"pubmed\">24637123</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson T.R., Debelius J.W., Thron T., Janssen S., Shastri G.G., Ilhan Z.E., Challis C., Schretter C.E., Rocha S., Gradinaru V., et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson&#x2019;s Disease. Cell. 2016;167:1469&#x2013;1480.e12. doi: 10.1016/j.cell.2016.11.018.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cell.2016.11.018</ArticleId><ArticleId IdType=\"pmc\">PMC5718049</ArticleId><ArticleId IdType=\"pubmed\">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler M., Goodwin B.L., Ruthven C.R. Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man. Nature. 1971;229:414&#x2013;415. doi: 10.1038/229414a0.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/229414a0</ArticleId><ArticleId IdType=\"pubmed\">4926994</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldin B.R., Peppercorn M.A., Goldman P. Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J. Pharmacol. Exp. Ther. 1973;186:160&#x2013;166. doi: 10.1016/S0022-3565(25)29577-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0022-3565(25)29577-5</ArticleId><ArticleId IdType=\"pubmed\">4723308</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel S.P., Frye A.K., El-Gendy A.O., Castejon M., Keshavarzian A., van Dijk G., El Aidy S. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson&#x2019;s disease. Nat. Commun. 2019;10:310. doi: 10.1038/s41467-019-08294-y.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41467-019-08294-y</ArticleId><ArticleId IdType=\"pmc\">PMC6338741</ArticleId><ArticleId IdType=\"pubmed\">30659181</ArticleId></ArticleIdList></Reference><Reference><Citation>Maini Rekdal V., Bess E.N., Bisanz J.E., Turnbaugh P.J., Balskus E.P. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019;364:eaau6323. doi: 10.1126/science.aau6323.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/science.aau6323</ArticleId><ArticleId IdType=\"pmc\">PMC7745125</ArticleId><ArticleId IdType=\"pubmed\">31196984</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldenberg M.M. Medical management of Parkinson&#x2019;s disease. Pharm. Ther. 2008;33:590&#x2013;606.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC2730785</ArticleId><ArticleId IdType=\"pubmed\">19750042</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng G., Hardy M., Hillard C.J., Feix J.B., Kalyanaraman B. Mitigating gut microbial degradation of levodopa and enhancing brain dopamine: Implications in Parkinson&#x2019;s disease. Commun. Biol. 2024;7:668. doi: 10.1038/s42003-024-06330-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s42003-024-06330-2</ArticleId><ArticleId IdType=\"pmc\">PMC11139878</ArticleId><ArticleId IdType=\"pubmed\">38816577</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez M., Calles-Enriquez M., Nes I., Martin M.C., Fernandez M., Ladero V., Alvarez M.A. Tyramine biosynthesis is transcriptionally induced at low pH and improves the fitness of Enterococcus faecalis in acidic environments. Appl. Microbiol. Biotechnol. 2015;99:3547&#x2013;3558. doi: 10.1007/s00253-014-6301-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00253-014-6301-7</ArticleId><ArticleId IdType=\"pubmed\">25529314</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler M., Johnson R.D., Ruthven C.R., Reid J.L., Calne D.B. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition. Nature. 1974;247:364&#x2013;366. doi: 10.1038/247364b0.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/247364b0</ArticleId><ArticleId IdType=\"pubmed\">4817854</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J., Lee Y., Cheng G., Zielonka J., Zhang Q., Bajzikova M., Xiong D., Tsaih S.W., Hardy M., Flister M., et al. Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity. iScience. 2018;3:192&#x2013;207. doi: 10.1016/j.isci.2018.04.013.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.isci.2018.04.013</ArticleId><ArticleId IdType=\"pmc\">PMC6137433</ArticleId><ArticleId IdType=\"pubmed\">30428319</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng G., Hardy M., You M., Kalyanaraman B. Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation. Sci. Rep. 2022;12:5143. doi: 10.1038/s41598-022-08984-6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-022-08984-6</ArticleId><ArticleId IdType=\"pmc\">PMC8948292</ArticleId><ArticleId IdType=\"pubmed\">35332210</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng G., Zhang Q., Pan J., Lee Y., Ouari O., Hardy M., Zielonka M., Myers C.R., Zielonka J., Weh K., et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat. Commun. 2019;10:2205. doi: 10.1038/s41467-019-10042-1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41467-019-10042-1</ArticleId><ArticleId IdType=\"pmc\">PMC6525201</ArticleId><ArticleId IdType=\"pubmed\">31101821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zielonka J., Joseph J., Sikora A., Hardy M., Ouari O., Vasquez-Vivar J., Cheng G., Lopez M., Kalyanaraman B. Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem. Rev. 2017;117:10043&#x2013;10120. doi: 10.1021/acs.chemrev.7b00042.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1021/acs.chemrev.7b00042</ArticleId><ArticleId IdType=\"pmc\">PMC5611849</ArticleId><ArticleId IdType=\"pubmed\">28654243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A., Langley M.R., Harischandra D.S., Neal M.L., Jin H., Anantharam V., Joseph J., Brenza T., Narasimhan B., Kanthasamy A., et al. Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson&#x2019;s Disease. J. Neuroimmune Pharmacol. 2016;11:259&#x2013;278. doi: 10.1007/s11481-016-9650-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11481-016-9650-4</ArticleId><ArticleId IdType=\"pmc\">PMC4995106</ArticleId><ArticleId IdType=\"pubmed\">26838361</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley M., Ghosh A., Charli A., Sarkar S., Ay M., Luo J., Zielonka J., Brenza T., Bennett B., Jin H., et al. Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice. Antioxid. Redox Signal. 2017;27:1048&#x2013;1066. doi: 10.1089/ars.2016.6905.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1089/ars.2016.6905</ArticleId><ArticleId IdType=\"pmc\">PMC5651937</ArticleId><ArticleId IdType=\"pubmed\">28375739</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A., Chandran K., Kalivendi S.V., Joseph J., Antholine W.E., Hillard C.J., Kanthasamy A., Kanthasamy A., Kalyanaraman B. Neuroprotection by a mitochondria-targeted drug in a Parkinson&#x2019;s disease model. Free Radic. Biol. Med. 2010;49:1674&#x2013;1684. doi: 10.1016/j.freeradbiomed.2010.08.028.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.freeradbiomed.2010.08.028</ArticleId><ArticleId IdType=\"pmc\">PMC4020411</ArticleId><ArticleId IdType=\"pubmed\">20828611</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow B.J., Rolfe F.L., Lockhart M.M., Frampton C.M., O&#x2019;Sullivan J.D., Fung V., Smith R.A., Murphy M.P., Taylor K.M., Protect Study G. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson&#x2019;s disease. Mov. Disord. 2010;25:1670&#x2013;1674. doi: 10.1002/mds.23148.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/mds.23148</ArticleId><ArticleId IdType=\"pubmed\">20568096</ArticleId></ArticleIdList></Reference><Reference><Citation>John P., Whatley F.R. Paracoccus denitrificans and the evolutionary origin of the mitochondrion. Nature. 1975;254:495&#x2013;498. doi: 10.1038/254495a0.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/254495a0</ArticleId><ArticleId IdType=\"pubmed\">235742</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy M.P., Smith R.A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 2007;47:629&#x2013;656. doi: 10.1146/annurev.pharmtox.47.120505.105110.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1146/annurev.pharmtox.47.120505.105110</ArticleId><ArticleId IdType=\"pubmed\">17014364</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazarov P.A., Osterman I.A., Tokarchuk A.V., Karakozova M.V., Korshunova G.A., Lyamzaev K.G., Skulachev M.V., Kotova E.A., Skulachev V.P., Antonenko Y.N. Mitochondria-targeted antioxidants as highly effective antibiotics. Sci. Rep. 2017;7:1394. doi: 10.1038/s41598-017-00802-8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-017-00802-8</ArticleId><ArticleId IdType=\"pmc\">PMC5431119</ArticleId><ArticleId IdType=\"pubmed\">28469140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari S., Jayakumar S., Gupta G.D., Bihani S.C., Sharma D., Kutala V.K., Sandur S.K., Kumar V. Antibacterial activity of new structural class of semisynthetic molecule, triphenyl-phosphonium conjugated diarylheptanoid. Free Radic. Biol. Med. 2019;143:140&#x2013;145. doi: 10.1016/j.freeradbiomed.2019.08.003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.freeradbiomed.2019.08.003</ArticleId><ArticleId IdType=\"pubmed\">31398499</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.H., Chang P.C., Wey S.P., Chen P.M., Chen C., Chan M.H. Therapeutic effects of honokiol on motor impairment in hemiparkinsonian mice are associated with reversing neurodegeneration and targeting PPARgamma regulation. Biomed. Pharmacother. 2018;108:254&#x2013;262. doi: 10.1016/j.biopha.2018.07.095.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.biopha.2018.07.095</ArticleId><ArticleId IdType=\"pubmed\">30223096</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.H., Chang P.C., Chen C., Chan M.H. Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson&#x2019;s disease. Pharmacol. Rep. 2018;70:668&#x2013;676. doi: 10.1016/j.pharep.2018.01.003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.pharep.2018.01.003</ArticleId><ArticleId IdType=\"pubmed\">29909247</ArticleId></ArticleIdList></Reference><Reference><Citation>Birth D., Kao W.C., Hunte C. Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action. Nat. Commun. 2014;5:4029. doi: 10.1038/ncomms5029.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ncomms5029</ArticleId><ArticleId IdType=\"pubmed\">24893593</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 2001;98:14669&#x2013;14674. doi: 10.1073/pnas.251341998.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1073/pnas.251341998</ArticleId><ArticleId IdType=\"pmc\">PMC64739</ArticleId><ArticleId IdType=\"pubmed\">11724929</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzarini M., Martin S., Mitkovski M., Vozari R.R., Stuhmer W., Bel E.D. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model. Glia. 2013;61:1084&#x2013;1100. doi: 10.1002/glia.22496.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/glia.22496</ArticleId><ArticleId IdType=\"pubmed\">23595698</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishbein S.R.S., Mahmud B., Dantas G. Antibiotic perturbations to the gut microbiome. Nat. Rev. Microbiol. 2023;21:772&#x2013;788. doi: 10.1038/s41579-023-00933-y.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41579-023-00933-y</ArticleId><ArticleId IdType=\"pmc\">PMC12087466</ArticleId><ArticleId IdType=\"pubmed\">37491458</ArticleId></ArticleIdList></Reference><Reference><Citation>Round J.L., Mazmanian S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 2009;9:313&#x2013;323. doi: 10.1038/nri2515.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/nri2515</ArticleId><ArticleId IdType=\"pmc\">PMC4095778</ArticleId><ArticleId IdType=\"pubmed\">19343057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubeda C., Taur Y., Jenq R.R., Equinda M.J., Son T., Samstein M., Viale A., Socci N.D., van den Brink M.R., Kamboj M., et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J. Clin. Invest. 2010;120:4332&#x2013;4341. doi: 10.1172/JCI43918.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1172/JCI43918</ArticleId><ArticleId IdType=\"pmc\">PMC2993598</ArticleId><ArticleId IdType=\"pubmed\">21099116</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>",
  "fetched_at": "2026-01-29T18:51:11.407Z"
}